Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328811 | 0.86 | PIK3CA (0.43) | PIK3CAPIK3R1MTORMAPK1KDM4E | |
| SCHEMBL3994283 | 0.84 | LMNA (0.41) | PIK3CAMTORPOLBHTTALDH1A1 | |
| SCHEMBL243285 | 0.83 | PIK3CA (0.40) | PIK3CAPIK3R1MTORGAAPOLB | |
| SCHEMBL21263157 | 0.83 | PIK3R1 (0.46) | PIK3CAPIK3R1MTOR | |
| SCHEMBL14803578 | 0.82 | ADORA2A (0.47) | PIK3CAPIK3R1MTORGAAPOLB | |
| SCHEMBL4124972 | 0.80 | KDM4E (0.41) | PIK3CAMTORKMT2AMEN1MAPK1 | |
| SCHEMBL3115454 | 0.78 | PIK3CA (0.39) | PIK3CAPIK3R1MTORKMT2AMEN1 | |
| SCHEMBL243584 | 0.77 | PIK3CA (0.41) | PIK3CAPIK3R1MTORKCNQ3KCNQ2 | |
| SCHEMBL17408814 | 0.76 | PIK3CA (0.39) | PIK3CAPIK3R1MTORKMT2AMEN1 | |
| SCHEMBL29439003 | 0.76 | SYK (0.37) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399260-A1 | ATR INHIBITOR AND APPLICATION THEREOF | Wuxi Biocity Biopharmaceutics Co., Ltd. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3753937-A1 | ATR INHIBITOR AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD. (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CA 26/4885PIK3R1 56/4885MTOR 294/4885 |
| US-20200399260-A1 | ATR INHIBITOR AND APPLICATION THEREOF | ATR, ATRIP, CHEK1 | PIK3CA 1191/4885PIK3R1 483/4885MTOR 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.